PROCEPT BioRobotics Corporation (PRCT) Operating Margin
- Operating margin · 12 months: Value -33.86%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -33.86% | Operating income / revenue. Period ending 2026-06-30. $-114.23M ÷ $337.34M × 100 ≈ -33.86% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -114.23M USD | Operating Income (Loss) |
| Revenue | 337.34M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 78.81M USD | Research and Development Expense |
| Selling, general and administration | 252.06M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-114.23M | $337.34M | (m) | $78.81M | $252.06M | -33.86% |
| 2026-03-31 | $-109.03M | $322.02M | (m) | $76.34M | $238.70M | -33.86% |
| 2025-12-31 | $-103.86M | $308.05M | (m) | $71.28M | $228.81M | -33.71% |
| 2025-09-30 | $-92.53M | $299.91M | (m) | $67.29M | $218.83M | -30.85% |
| 2025-06-30 | $-91.76M | $274.95M | (m) | $65.75M | $202.51M | -33.37% |
| 2025-03-31 | $-96.40M | $249.12M | (m) | $65.62M | $187.01M | -38.70% |
| 2024-12-31 | $-96.61M | $224.50M | (m) | $62.30M | $171.41M | -43.04% |
| 2024-09-30 | $-106.46M | $199.84M | (m) | $61.73M | $159.41M | -53.27% |
| 2024-06-30 | $-109.64M | $176.57M | (m) | $56.68M | $149.61M | -62.09% |
| 2024-03-31 | $-108.44M | $156.33M | (m) | $50.79M | $141.24M | -69.37% |
| 2023-12-31 | $-109.17M | $136.19M | (m) | $48.45M | $131.77M | -80.16% |
| 2023-09-30 | $-104.65M | $116.39M | (m) | $43.63M | $121.49M | -89.92% |
| 2023-06-30 | $-101.15M | $101.63M | (m) | $39.61M | $113.36M | -99.52% |
| 2023-03-31 | $-93.40M | $85.22M | (m) | $34.71M | $100.57M | -109.59% |
| 2022-12-31 | $-80.72M | $75.01M | (m) | $28.98M | $88.83M | -107.61% |
| 2022-09-30 | $-72.52M | $61.38M | (m) | $24.38M | $79.06M | -118.15% |
| 2022-06-30 | $-63.21M | $49.69M | (m) | $21.71M | $66.43M | -127.19% |
| 2022-03-31 | $-58.52M | $41.48M | (m) | $19.48M | $59.07M | -141.10% |
| 2021-12-31 | $-54.16M | $34.47M | (m) | $18.99M | $51.04M | -157.12% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-47.80M | $7.72M | (m) | $16.27M | $30.27M | -619.44% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |